Methylprednisolone

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Asthma, Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Every registered study for this drug was reviewed, and none was selected as featured evidence for its approved use, so its Featured trials section is empty.

Also approved (1)
US
  • MEDROL (methylprednisolone) tablets (Pfizer): corticosteroid-responsive conditions, including allergic states such as bronchial asthma and gastrointestinal diseases (ulcerative colitis, regional enteritis)
Product first approved 1957Outside this platform's coverageFDA label

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

This page stands for the molecule. Studies that name only the molecule, and no branded product, are listed here and are marked as studies of the molecule. A study of a branded product is on that product's page.

Phase 3 (136)
Rheumatoid Arthritis
NCT02006706 · Hoffmann-La Roche
2006-08-10 – 2007-11-23 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07478003 · Thomas Engstrom
2026-04-20 – 2036-04-01 · STEMI - ST Elevation Myocardial Infarction
What this study did
NCT03007147 · Children's Oncology Group
2017-08-08 – 2034-09-30 · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
What this study did
NCT04270409 · Sanofi
2020-06-16 – 2033-10-21 · Plasma Cell Myeloma
What this study did
NCT04702256 · Assistance Publique - Hôpitaux de Paris
2021-12-09 – 2031-12 · Lupus Nephritis, Systemic Lupus Erythematosus (SLE)
What this study did
NCT04221477 · Hoffmann-La Roche
2020-08-10 – 2031-03-02 · Lupus Nephritis
What this study did
NCT06360458 · Wan-Jin Chen
2024-08-01 – 2030-06-30 · Acute Ischemic Stroke, Large Infarct Core
What this study did
NCT06474273 · University of Sydney
2026-03-13 – 2030-06 · Rejection; Transplant, Kidney, Rejection; Transplant, Pancreas
What this study did
NCT05139849 · Tiohundra AB
2026-10-12 – 2029-06-30 · Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical Trial
What this study did
NCT04688788 · Copenhagen University Hospital, Rigshospitalet
2021-04-28 – 2029-06-10 · Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis
What this study did
NCT06870448 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-04 – 2029-04 · Acute Ischemic Stroke
What this study did
NCT07507643 · Memorial Sloan Kettering Cancer Center
2026-03-27 – 2029-03-27 · Hepatectomy
What this study did
NCT05150704 · Niguarda Hospital
2021-10-07 – 2028-12 · Myocarditis Acute
What this study did
NCT07352865 · Qingyuan Zhan
2026-01-15 – 2028-11-30 · Psittacosis
What this study did
NCT07351500 · Qingyuan Zhan
2026-01-15 – 2028-11-30 · Influenza
What this study did
NCT07371572 · Sint Maartenskliniek
2025-10-28 – 2028-11 · Hand Osteoarthritis
What this study did
NCT07650396 · Erasmus Medical Center
2026-06-03 – 2028-10-31 · Achilles Tendinopathy (AT)
What this study did
NCT05974462 · University Hospital, Antwerp
2024-05-24 – 2028-10-01 · Acute Myocarditis
What this study did
NCT05947669 · Odense University Hospital
2023-08-22 – 2028-09 · Colitis
What this study did
NCT06522100 · Assistance Publique - Hôpitaux de Paris
2025-02-01 – 2028-08-16 · Acute Myocarditis
What this study did
NCT07141303 · Tang-Du Hospital
2025-08-08 – 2028-06-30 · Acute Ischemic Stroke
What this study did
NCT03249844 · Centre Hospitalier Universitaire de Saint Etienne
2022-09-01 – 2027-12-31 · Arterial Ischemic Stroke
What this study did
NCT07152600 · Qingyuan Zhan
2026-02-01 – 2027-12-31 · Adenovirus Infections, Human
What this study did
NCT04629248 · Hoffmann-La Roche
2021-06-25 – 2027-12-21 · Primary Membranous Nephropathy
What this study did
NCT06266221 · Assistance Publique - Hôpitaux de Paris
2024-05-01 – 2027-11-01 · Erythema Multiforme
What this study did
NCT05405166 · Sanofi
2022-06-23 – 2027-10-22 · Plasma Cell Myeloma Recurrent
What this study did
NCT02166463 · National Cancer Institute (NCI)
2015-03-19 – 2027-10-14 · Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma, Ann Arbor Stage IVB Hodgkin Lymphoma, Childhood Hodgkin Lymphoma, Classic Hodgkin Lymphoma
What this study did
NCT07202143 · YiLin
2025-09-01 – 2027-09-30 · Large Infarct Core, Post-stroke Lymphocytopenia
What this study did
NCT04548999 · Hoffmann-La Roche
2020-12-03 – 2027-09-08 · Multiple Sclerosis
What this study did
NCT03875690 · Centre Hospitalier Universitaire Dijon
2019-07-02 – 2027-09 · Elective Surgery for Any Digestive Cancer
What this study did
NCT04544436 · Hoffmann-La Roche
2020-11-26 – 2027-04-01 · Multiple Sclerosis
What this study did
NCT06848374 · University Health Network, Toronto
2024-12-20 – 2026-12-31 · Adhesive Capsulitis of the Shoulder
What this study did
NCT05058287 · Hospital for Special Surgery, New York
2021-11-05 – 2026-12-31 · Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative, Pain, Back
What this study did
NCT06045013 · General and Veteran Hospital Croatian Pride Knin
2023-09-13 – 2026-08-30 · Carpal Tunnel Syndrome
What this study did
NCT05627557 · Hoffmann-La Roche
2023-03-29 – 2026-08-27 · Childhood Idiopathic Nephrotic Syndrome
What this study did
NCT07317596 · Sana'a University
2024-06-27 – 2026-07-15 · Wisdom Tooth Removal, Post Operative Complications, Hyaluronic Acid, Methylprednisolone
What this study did
NCT04873583 · Insel Gruppe AG, University Hospital Bern
2021-11-16 – 2026-07 · Paediatric Stroke
What this study did
NCT05324748 · Leiden University Medical Center
2022-11-07 – 2026-06 · Cluster Headache
What this study did
NCT03368664 · Genzyme, a Sanofi Company
2017-10-23 – 2025-09-08 · Multiple Sclerosis
What this study did
NCT04163536 · Versailles Hospital
2021-10-25 – 2025-04-17 · Chronic Obstructive Pulmonary Disease
What this study did
NCT03942887 · Leiden University Medical Center
2019-05-03 – 2025-04-01 · ANCA Associated Vasculitis
What this study did
NCT05863936 · Nanjing University School of Medicine
2023-04-01 – 2024-12-31 · Lupus Nephritis, Remission, Safety Issues
What this study did
NCT03745664 · University of Roma La Sapienza
2021-01-10 – 2024-09-01 · Community-acquired Pneumonia
What this study did
NCT00557193 · Children's Oncology Group
2008-01-15 – 2024-06-30 · Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
What this study did
NCT02444429 · Hospices Civils de Lyon
2015-09-02 – 2024-06-21 · Renal Transplantation
What this study did
NCT05137496 · Beijing Friendship Hospital
2022-06-01 – 2024-06-01 · Macrophage Activation Syndrome
What this study did
NCT04833374 · Sixth Affiliated Hospital, Sun Yat-sen University
2021-05-24 – 2023-12-31 · IgA Nephropathy
What this study did
Phase 2/3 (39)
Other / comorbidity
NCT07072585 · Children's Oncology Group
2026-08-28 – 2035-09-01 · Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
What this study did
NCT07412470 · Sanofi
2026-03-13 – 2033-08-15 · Kidney Transplant Rejection
What this study did
NCT04787744 · VA Office of Research and Development
2021-07-01 – 2029-03-30 · Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
What this study did
NCT07542288 · The Second Affiliated Hospital of Hainan Medical University
2026-04-15 – 2028-06-30 · Brain Metastases From Solid Tumors
What this study did
NCT03829566 · Northwestern University
2019-11 – 2025-11-28 · Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
What this study did
NCT04007328 · Taipei Medical University WanFang Hospital
2019-06-15 – 2025-11 · Pneumonia, Bacterial
What this study did
NCT06496997 · Fayoum University
2024-08-01 – 2025-08-01 · Acute Respiratory Distress Syndrome
What this study did
NCT01228331 · Universitätsklinikum Hamburg-Eppendorf
2010-10 – 2024-11-20 · Leukemia
What this study did
NCT02422368 · Iran University of Medical Sciences
2022-09-01 – 2024-11 · Thyroid Eye Disease
What this study did
NCT04898231 · University of California, San Diego
2020-12-22 – 2024-04-25 · Multisystem Inflammatory Syndrome-Children
What this study did
NCT03584516 · Incyte Corporation
2019-01-17 – 2023-11-03 · Chronic Graft-versus-host Disease
What this study did
NCT04942002 · Asociación para Evitar la Ceguera en México
2021-06-15 – 2023-09-15 · Optic Neuritis, Treatment, Methylprednisolone
What this study did
NCT05003596 · Robert Wood Johnson Barnabas Health
2021-09-01 – 2023-09-01 · Hand Injuries, Finger Injuries
What this study did
NCT05752305 · Universidad de Granada
2022-01-15 – 2023-07-15 · Inflammation, Pain, Postoperative, Trismus
What this study did
NCT05951504 · University of Manitoba
2022-06-22 – 2023-07-01 · Odontogenic Infection of Jaw (Disorder)
What this study did
NCT03876444 · Suvasini Sharma
2019-04-01 – 2022-10-31 · Infantile Spasm
What this study did
NCT02578394 · Mid and South Essex NHS Foundation Trust
2016-04 – 2022-01-26 · Gout, Chronic Kidney Diseases
What this study did
NCT03640949 · Lars Wiuff Andersen
2018-09-17 – 2022-01-21 · Heart Arrest
What this study did
NCT04074187 · Sanofi
2019-10-21 – 2021-05-19 · Thrombotic Thrombocytopenic Purpura
What this study did
NCT03564106 · Assiut University
2019-03-01 – 2021-01-15 · Pain Management
What this study did
NCT04349410 · The Camelot Foundation
2020-04-11 – 2020-09-14 · CoVid 19 Positive
What this study did
NCT04693312 · Assiut University
2020-01-01 – 2020-07-01 · Pain, Chronic
What this study did
NCT04244591 · Peking Union Medical College Hospital
2020-01-26 – 2020-04-13 · COVID-19 Infections
What this study did
NCT00720109 · National Cancer Institute (NCI)
2008-07-14 – 2020-03-31 · Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
What this study did
NCT03593902 · Northwestern University
2018-05-17 – 2019-10-09 · Systemic Sclerosis, Scleroderma
What this study did
NCT01997658 · University of Calgary
2014-10 – 2018-10-30 · Complications
What this study did
NCT02445898 · Copenhagen University Hospital, Rigshospitalet
2015-09 – 2017-01 · Osteoarthrosis
What this study did
NCT02542592 · Copenhagen University Hospital, Rigshospitalet
2015-09 – 2017-01 · Osteoarthrosis
What this study did
NCT00455312 · Masonic Cancer Center, University of Minnesota
2007-08 – 2016-06 · Dyskeratosis Congenita, Aplastic Anemia
What this study did
NCT00802529 · Imperial College London
2009-04 – 2015-05 · Meniere's Disease
What this study did
NCT00595335 · Rebecca Bahn
2008-04 – 2013-09 · Thyroid-associated Ophthalmopathy
What this study did
NCT00806871 · Region Skane
2008-11 – 2012-04 · Carpal Tunnel Syndrome
What this study did
NCT00891306 · Amsterdam Molecular Therapeutics
2009-02 – 2011-04 · Familial Lipoprotein Lipase Deficiency
What this study did
NCT00104299 · National Institute of Allergy and Infectious Diseases (NIAID)
2005-01 – 2010-01 · Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
What this study did
NCT00562835 · Catholic University of the Sacred Heart
2008-02 – 2009-02 · Acute Lung Injury, ARDS, Human
What this study did
NCT00135967 · Radboud University Medical Center
started 2002-05 · Glomerulonephritis, Membranous
What this study did
NCT00003187 · Virginia Commonwealth University
1995-05 – 2005-02 · Leukemia, Lymphoma, Myelodysplastic Syndromes
What this study did
NCT00004255 · Chimeric Therapies
2000-03 – 2003-05 · Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
What this study did
Phase 2 (180)
Asthma
NCT07455396 · Johns Hopkins All Children's Hospital
2026-08-01 – 2028-08-14 · Asthma (Diagnosis)
What this study did
Crohn's Disease
NCT03219359 · Aaron Etra
2018-02-22 – 2028-10 · Crohn Disease
What this study did
Rheumatoid Arthritis
NCT02093026 · Hoffmann-La Roche
2002-08 – 2012-12 · Rheumatoid Arthritis
What this study did
NCT00634933 · Pfizer
2008-03 – 2012-10 · Arthritis, Rheumatoid
What this study did
NCT00243412 · Genentech, Inc.
2005-08 – 2009-02 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT04305145 · Massachusetts General Hospital
2020-08-31 – 2030-06-30 · Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
What this study did
NCT07763210 · Vanderbilt-Ingram Cancer Center
2026-09-25 – 2029-10-01 · Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma
What this study did
NCT01624805 · M.D. Anderson Cancer Center
2012-06-25 – 2029-06-30 · Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome
What this study did
NCT05303792 · Alliance for Clinical Trials in Oncology
2023-06-09 – 2029-05 · B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
What this study did
NCT06676579 · Mayo Clinic
2025-06-09 – 2029-03 · IgA Nephropathy (IgAN)
What this study did
NCT06471556 · Assistance Publique - Hôpitaux de Paris
2025-06-30 – 2029-02-28 · Neuroendocrine Cell Hyperplasia of Infancy
What this study did
NCT03579875 · Masonic Cancer Center, University of Minnesota
2018-11-13 – 2029-01-05 · Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders
What this study did
NCT02784210 · National Institute of Neurological Disorders and Stroke (NINDS)
2016-10-05 – 2028-12-31 · Multiple Sclerosis
What this study did
NCT06317662 · National Cancer Institute (NCI)
2025-06-05 – 2028-12-31 · Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
What this study did
NCT04936854 · Haukeland University Hospital
2023-01-01 – 2028-12 · Thyroid-Associated Ophthalmopathy
What this study did
NCT06730308 · Sun Yat-sen University
2024-11-20 – 2028-11-19 · Thymoma
What this study did
NCT07902609 · First Affiliated Hospital, Sun Yat-Sen University
2026-06-20 – 2028-06-30 · Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR)
What this study did
NCT07511582 · Bin Du
2026-04-15 – 2028-06-01 · Sepsis, Acute Respiratory Distress Syndrome
What this study did
NCT06373211 · Assistance Publique - Hôpitaux de Paris
2025-01-10 – 2028-06 · Paraneoplastic Sensory Neuronopathy
What this study did
NCT05704049 · Sanofi
2023-04-05 – 2028-05-12 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT06936566 · John Levine
2025-05-14 – 2028-04-14 · Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
What this study did
NCT05279092 · Yale University
2022-09-08 – 2028-03 · Total Knee Replacement, Knee Arthroplasty
What this study did
NCT05736549 · Yale University
2023-02-07 – 2028-03 · Total Knee Replacement, Knee Arthroplasty
What this study did
NCT07516522 · Tang-Du Hospital
2026-03-31 – 2027-12-31 · Ischemia Stroke, Thrombectomy, Large Vessel Occlusion
What this study did
NCT07509749 · Daihong Liu
2025-06-30 – 2027-12-30 · GVHD, Acute, Stem Cell Transplant Complications
What this study did
NCT06780202 · Emory University
2025-01-27 – 2027-12 · Foot Injuries and Disorders, Ankle Injuries and Disorders, Achilles Tendon Injury
What this study did
NCT07185633 · Bin Gu
2026-01-01 – 2027-10-01 · aGVHD
What this study did
NCT06356571 · Sanofi
2025-03-17 – 2027-07-15 · Plasma Cell Myeloma Refractory
What this study did
NCT05734625 · Mayo Clinic
2023-07-10 – 2027-07 · Episodic Migraine
What this study did
NCT07054801 · Daniel Raper, MBBS
2026-06-23 – 2027-06-01 · Headaches Associated With Subarachnoid Hemorrhage (SAH)
What this study did
NCT06670521 · University of Colorado, Denver
2024-12-02 – 2027-05-31 · Dysphagia, Laryngeal Edema
What this study did
NCT04862221 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
2022-02-09 – 2027-02 · Acute Liver Failure, Fulminant Hepatic Failure, Hepatic Encephalopathy, Acute Liver Injury, Immune Dysregulation
What this study did
NCT00792948 · National Cancer Institute (NCI)
2009-09-01 – 2027-01-06 · Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Adult L1 Acute Lymphoblastic Leukemia, Adult L2 Acute Lymphoblastic Leukemia, Adult T Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia
What this study did
NCT06768294 · I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
2025-01 – 2027-01 · Calcium Pyrophosphate Deposition Disease, Chondrocalcinosis
What this study did
NCT06841705 · Shilpa Grover, MD, MPH
2025-07-15 – 2026-12-31 · Immune Checkpoint Inhibitor-Related Colitis
What this study did
NCT04216524 · M.D. Anderson Cancer Center
2020-05-29 – 2026-12-31 · Blastic Plasmacytoid Dendritic Cell Neoplasm
What this study did
NCT04918953 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-06-02 – 2026-12-30 · Outcome
What this study did
NCT06673394 · Tianjin Medical University General Hospital
2025-09-03 – 2026-12-01 · Neuromyelitis Optica Spectrum Disorder Attack
What this study did
NCT07208799 · Nishtar Medical University
2026-01-03 – 2026-12-01 · Mandible Fracture, Edema Face, Pain Management, Corticosteroid Injection
What this study did
NCT07184840 · Tianjin Medical University General Hospital
2025-09-09 – 2026-09-30 · Neuromyelitis Optica Spectrum Disorder Attack
What this study did
NCT04479267 · Barbara Ann Karmanos Cancer Institute
2020-08-21 – 2026-07-19 · Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6 Rearrangements, Double Expressor Lymphoma, High-grade B-cell Lymphoma
What this study did
NCT06497374 · Tianjin Medical University General Hospital
2024-07-05 – 2026-06-30 · Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder
What this study did
NCT04438382 · ECOG-ACRIN Cancer Research Group
2021-01-07 – 2026-05-26 · Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Steroid-Refractory Pneumonitis
What this study did
NCT05986422 · Charite University, Berlin, Germany
2023-10-01 – 2026-02-19 · Post-COVID-19 Syndrome
What this study did
NCT04810156 · Inge Marie Svane
2021-04-07 – 2025-11-07 · Hepatitis, Drug-Induced
What this study did
NCT03913559 · St. Jude Children's Research Hospital
2019-05-14 – 2025-09-15 · Acute Lymphoblastic Leukemia
What this study did
NCT05368181 · Sichuan University
2022-05-01 – 2024-12-31 · GVHD,Acute, Stem Cell Transplant Complications
What this study did
NCT05462730 · Thomas Engstrom
2022-11-14 – 2024-10-17 · ST Elevation Myocardial Infarction, Inflammatory Response, Myocardial Reperfusion Injury, Myocardial Injury
What this study did
Phase 1/2 (41)
Crohn's Disease
NCT04224558 · Cedars-Sinai Medical Center
2019-11-15 – 2027-09-30 · Crohn Disease
What this study did
Other / comorbidity
NCT07270549 · CTNNB1 Foundation
2025-11-01 – 2032-12-31 · CTNNB1 Neurodevelopmental Syndrome
What this study did
NCT04127578 · Prevail Therapeutics
2020-01-03 – 2031-08-31 · Parkinson Disease
What this study did
NCT03952637 · National Human Genome Research Institute (NHGRI)
2019-08-19 – 2030-01-01 · Lysosomal Diseases, Gangliosidosis, GM1
What this study did
NCT04408625 · Prevail Therapeutics
2020-11-09 – 2029-11-30 · Frontotemporal Dementia
What this study did
NCT07357935 · Qingyuan Zhan
2026-02-01 – 2028-10-01 · Acute Respiratory Failure, Community-Acquired Pneumonia
What this study did
NCT07525466 · Beijing Tongren Hospital
2026-04-01 – 2028-09-30 · Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH)
What this study did
NCT07052929 · Astellas Gene Therapies
2025-12-15 – 2027-10-31 · X-Linked Myotubular Myopathy
What this study did
NCT07287397 · Vector Y Therapeutics
2025-12-19 – 2027-10-15 · Amyotrophic Lateral Sclerosis
What this study did
NCT06809998 · Unity Health Toronto
2025-01-24 – 2027-08-30 · Total Knee Anthroplasty, Osteoarthritis(Primary), Osteoarthritis (OA) of the Knee, Bilateral Knee Osteoarthritis
What this study did
NCT04151082 · M.D. Anderson Cancer Center
2019-10-16 – 2027-07-31 · Cranial Nerve Disorder, Head and Neck Carcinoma, Oropharyngeal Carcinoma
What this study did
NCT04411654 · Prevail Therapeutics
2021-06-29 – 2027-02 · Gaucher Disease, Type 2
What this study did
NCT06656962 · Renmin Hospital of Wuhan University
2024-10-10 – 2026-10-30 · Antineutrophil Cytoplasmic Antibody (ANCA)-associated Nephritis (AAGN)
What this study did
NCT07101367 · Ain Shams University
2025-09-01 – 2026-08-31 · Coronary Artery Disease, Systemic Inflammatory Response Syndrome, Postoperative Complications
What this study did
NCT02061800 · Diane George
2013-06-03 – 2026-07 · Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
What this study did
NCT05640375 · Baskent University
2019-12-24 – 2023-12-24 · Intussusception
What this study did
NCT04066114 · National Institute of Allergy and Infectious Diseases (NIAID)
2019-12-11 – 2023-09-14 · Living-Donor Kidney Transplant, Kidney Transplant Recipients
What this study did
NCT02348216 · Kite, A Gilead Company
2015-04-21 – 2023-07-27 · Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
What this study did
NCT05476679 · Raziel Therapeutics Ltd.
2022-09-25 – 2023-06-12 · Submental Fat
What this study did
NCT03266146 · Beijing 302 Hospital
2017-09-02 – 2023-01-31 · Drug-induced Liver Injury,Chronic
What this study did
NCT04294459 · Sanofi
2020-06-18 – 2022-05-02 · Immune System Disorder
What this study did
NCT04219995 · Louisiana State University Health Sciences Center in New Orleans
2020-02-03 – 2021-02 · Intractable Epilepsy, Convulsive Seizures
What this study did
NCT04220632 · Innovent Biologics (Suzhou) Co. Ltd.
2020-06-18 – 2020-10-10 · GVHD,Acute
What this study did
NCT00630253 · Masonic Cancer Center, University of Minnesota
2000-02-17 – 2020-10-10 · Fanconi Anemia
What this study did
NCT02464657 · M.D. Anderson Cancer Center
2015-07 – 2020-05-07 · Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT02282514 · Northwestern University
2014-10 – 2019-08-30 · Stiff-Person Syndrome
What this study did
NCT02651350 · Beijing 302 Hospital
2015-12 – 2019-07 · Drug-induced Liver Injury,Chronic
What this study did
NCT00787722 · Northwestern University
2009-10-10 – 2018-11 · Devic's Disease
What this study did
NCT02790788 · University of Athens
2016-11-04 – 2018-08-11 · Inhospital Cardiac Arrest
What this study did
NCT00579527 · Sumitomo Pharma Switzerland GmbH
2005-12-19 – 2017-12-31 · DiGeorge Anomaly, Complete DiGeorge Anomaly, Complete Atypical DiGeorge Anomaly, Complete DiGeorge Syndrome, Complete Atypical DiGeorge Syndrome
What this study did
NCT02049073 · Washington University School of Medicine
2017-10-31 – 2017-11-01 · Noise-induced Hearing Loss
What this study did
NCT01875237 · M.D. Anderson Cancer Center
2013-12-27 – 2017-03-07 · Leukemia, Myeloma, Myeloproliferative Diseases
What this study did
NCT02535039 · Shengjing Hospital
2015-10 – 2016-12 · Postoperative Complication, Cognitive Retention Disorder
What this study did
NCT01046786 · China Spinal Cord Injury Network
2010-01 – 2013-12 · Spinal Cord Injuries
What this study did
NCT01354483 · China Spinal Cord Injury Network
2011-09 – 2013-12 · Spinal Cord Injuries
What this study did
NCT01647685 · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
2012-05 – 2013-05 · Atherosclerosis
What this study did
NCT01014104 · Royan Institute
2009-10 – 2010-12 · Ovarian Hyperstimulation Syndrome
What this study did
NCT00609739 · Masonic Cancer Center, University of Minnesota
1999-06 – 2010-06 · Leukemia
What this study did
NCT00078559 · University of Wisconsin, Madison
2003-11 – 2010-02 · Kidney Transplantation, Kidney Disease
What this study did
NCT00002831 · M.D. Anderson Cancer Center
1995-08-01 – 2002-12-31 · Leukemia
What this study did
Phase 1 (59)
Rheumatoid Arthritis
NCT01390441 · Merck Sharp & Dohme LLC
2011-07 – 2014-04 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05587673 · Stanford University
2022-10-06 – 2024-10-11 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis
What this study did
Other / comorbidity
NCT07803978 · Chinese PLA General Hospital
2026-05-01 – 2029-05-01 · Acute Gastrointestinal Graft-versus-host Disease
What this study did
NCT06209606 · Oncotherapeutics
2022-12-08 – 2029-02 · Multiple Myeloma
What this study did
NCT06081101 · McMaster University
2025-03-01 – 2028-07 · Sacro-iliac Joint Pain
What this study did
NCT07762105 · Banu Aji Dibyasakti
2026-08-30 – 2027-09-30 · Thyroid Eye Disease, Graves Ophthalmopathy, Graves Orbitopathy
What this study did
NCT07070882 · Columbia University
2025-06-20 – 2027-06-20 · Osteoarthritis, Knee
What this study did
NCT06225310 · Oncotherapeutics
2024-08-06 – 2027-05-01 · Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
What this study did
NCT03110822 · Oncotherapeutics
2017-02-01 – 2027-02 · Multiple Myeloma
What this study did
NCT06917859 · Ain Shams University
2025-02-01 – 2026-12-01 · Cardiopulmonary Bypass, AKI - Acute Kidney Injury
What this study did
Cyclosporine Vs Steroids in DRESSenrolling by invitation
NCT04988256 · University of Southern California
2021-09-27 – 2026-06-30 · DRESS Syndrome, Drug-Induced Hypersensitivity Syndrome
What this study did
NCT06119490 · Peng Zhang
2023-07-05 – 2025-11-09 · Toxic Epidermal Necrolysis
What this study did
NCT07081399 · Damanhour University
2024-08-08 – 2025-08 · Dysphagia, Dysphagia Rehabilitation
What this study did
NCT06462781 · The Cooper Health System
2024-03-15 – 2025-06-01 · Refractory Migraine
What this study did
NCT05823675 · Biotech Pharmaceutical Co., Ltd.
2023-05-19 – 2025-02 · Acute Graft Versus Host Disease
What this study did
NCT06453083 · University of Utah
2023-01-13 – 2024-12-17 · Pain
What this study did
NCT05280873 · Zhou Chengzhi
2021-10-10 – 2024-10-20 · Pneumonitis, Malignant Tumor
What this study did
NCT04599634 · National Cancer Institute (NCI)
2021-12-16 – 2024-06-20 · Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Lymphoma, B-Cell Lymphoma
What this study did
NCT04666129 · Sumitomo Pharma America, Inc.
2021-02-18 – 2024-05-28 · Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
What this study did
NCT01331018 · Fred Hutchinson Cancer Center
2012-02-22 – 2024-02-15 · Fanconi Anemia
What this study did
NCT02867800 · Monica Bhatia
2016-07 – 2023-12-30 · Sickle Cell Disease, Graft Versus Host Disease
What this study did
NCT04519476 · Oncotherapeutics
2020-11-01 – 2023-12-29 · Refractory Multiple Myeloma
What this study did
NCT05532072 · First Affiliated Hospital Xi'an Jiaotong University
2022-09 – 2023-09 · Graves Ophthalmopathy
What this study did
NCT04509219 · Chang Gung Memorial Hospital
2020-04-15 – 2023-08-31 · Mucocutaneous Lymph Node Syndrome
What this study did
NCT05655130 · Indiana Hand to Shoulder Center
2018-11-06 – 2023-05-02 · Fractures, Bone, Fractures, Closed, Radius Fracture Distal
What this study did
NCT05317624 · Alexandria University
2021-08-10 – 2023-02-01 · Shoulder Pain
What this study did
NCT02798523 · National Institute of Allergy and Infectious Diseases (NIAID)
2017-01-24 – 2022-11-14 · Normal Physiology
What this study did
NCT06802432 · Ain Shams University
2022-01-01 – 2022-09-01 · Post Operative Arrythmia, Anesthesia, Cardiac Surgery, Corticosteroids
What this study did
NCT04233164 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2020-03-04 – 2022-05-03 · Systemic Lupus Erythematous (SLE)
What this study did
NCT03059979 · Radboud University Medical Center
2017-01 – 2021-07-01 · Systemic Sclerosis, Raynaud Phenomena
What this study did
NCT02583594 · Genzyme, a Sanofi Company
2015-12-06 – 2021-03-01 · Progressive Multiple Sclerosis
What this study did
NCT04532775 · Fayoum University
2020-08-30 – 2020-12 · Neuropathy, Pain
What this study did
NCT02779283 · OHSU Knight Cancer Institute
2016-01-13 – 2018-09-20 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
What this study did
NCT00376480 · Dana-Farber Cancer Institute
2005-06 – 2018-05-16 · Leukemia, Myelodysplastic Syndromes
What this study did
NCT02424435 · Children's Hospital of Philadelphia
2015-06 – 2018-04 · Friedreich Ataxia
What this study did
NCT02293109 · Mehrdad Abedi, MD
2015-12-17 – 2018-01-11 · Contiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia
What this study did
NCT02995083 · Rush University Medical Center
2017-06 – 2018-01 · Symptomatic Osteoarthritis of the Knee
What this study did
NCT02680548 · University Health Network, Toronto
2015-11 – 2017-12 · CHRONIC POST-TRAUMATIC NEUROPATHIC PAIN IN ANKLE AND FOOT
What this study did
NCT00278564 · Northwestern University
2005-09 – 2016-07 · MYOPATHY
What this study did
NCT00424489 · Northwestern University
2002-02 – 2016-06 · Myasthenia Gravis
What this study did
NCT02087813 · Stanford University
2014-03 – 2016-03 · Neuromyelitis Optica
What this study did
NCT02212210 · Medical University of South Carolina
2012-02 – 2015-10 · Fever, Labor Pain, Complication of Anesthesia During Pregnancy, Unspecified
What this study did
NCT02048358 · BBB-Therapeutics B.V.
2013-11 – 2015-02 · Healthy Volunteers, Multiple Sclerosis
What this study did
NCT00436761 · Milton S. Hershey Medical Center
started 2004-05 · Unspecified Childhood Solid Tumor, Protocol Specific
What this study did
NCT01886209 · Vertex Pharmaceuticals Incorporated
2013-06 – 2013-08 · Drug Interactions
What this study did
NCT01468415 · Assaf-Harofeh Medical Center
2011-06 – 2013-06 · Back Pain
What this study did
NCT01529320 · Fundacion IMIM
2012-02 – 2012-05 · Allergic Contact Eczema
What this study did
NCT01405157 · Pfizer
2012-01-01 – 2012-02-20 · Therapeutic Equivalency
What this study did
NCT01405131 · Pfizer
2012-01-01 – 2012-02-20 · Therapeutic Equivalency
What this study did
NCT01405170 · Pfizer
2011-10-14 – 2012-02-20 · Therapeutic Equivalency
What this study did
Phase 4 (142)
Rheumatoid Arthritis
NCT02451748 · University of Illinois at Chicago
2015-08 – 2017-12 · Rheumatoid Arthritis
What this study did
NCT01382940 · Hoffmann-La Roche
2011-07-26 – 2013-01-06 · Rheumatoid Arthritis
What this study did
NCT01000610 · Hoffmann-La Roche
2008-03-17 – 2012-05-16 · Rheumatoid Arthritis
What this study did
NCT00396747 · Université Catholique de Louvain
2003-06 – 2005-09 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05867329 · Berinstein, Jeffrey
2023-09-30 – 2027-11 · Ulcerative Colitis Acute
What this study did
NCT02921555 · Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
2018-10-11 – 2022-11-07 · Ulcerative Colitis
What this study did
NCT01941589 · Sheba Medical Center
2013-09 – 2021-04 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT07158476 · St. Louis University
2025-10-21 – 2031-09 · ACL Surgery, Pain Management
What this study did
NCT07605923 · University of Alabama at Birmingham
2026-09 – 2031-08 · ACL Reconstruction
What this study did
NCT06892210 · Copenhagen Respiratory Research
2026-03-10 – 2030-11-01 · Chronic Obstructive Pulmonary Disease (COPD)
What this study did
NCT06892197 · Copenhagen Respiratory Research
2026-03-10 – 2030-11-01 · Community Acquired Pneumonia (CAP)
What this study did
NCT07703098 · University Medical Centre Ljubljana
2026-09-01 – 2030-09-01 · Adrenal Insufficiency
What this study did
NCT07762170 · Igor Wilderman. MD
2026-07-30 – 2030-03 · Back Pain Lower Back, Neck Pain, Radiculopathy Multiple Sites, Spinal Stenosis Cervicothoracic Region, Spinal Stenosis Lumbar, Failed Back Surgery Syndrome (FBSS), Sciatica, Intervertebral Disc Disorders With Radiculopathy, Lumbar Region, Spine Osteoarthritis
What this study did
NCT06040255 · University of California, San Francisco
2023-10-01 – 2030-01-31 · Pediatric Stroke, Arteriopathy, Arterial Ischemic Stroke
What this study did
NCT07180277 · Zhangjiagang First People's Hospital
2026-03-29 – 2029-07-31 · Traumatic Brain Injury
What this study did
NCT07902843 · The Hawkins Foundation
2026-12-01 – 2029-04-30 · Shoulder
What this study did
NCT03661645 · Emory University
2018-09-07 – 2029-01 · Orthopedic Surgeries
What this study did
NCT07353749 · Duan Chuanzhi
2026-11-30 – 2028-12-31 · Unruptured Intracranial Aneurysms, Cerebrovascular Event, Hemorrhagic Stroke, Methylprednisolone, Flow Diverter
What this study did
NCT06968507 · Dr. Lutfi Kirdar Kartal Training and Research Hospital
2024-12-25 – 2028-09-10 · Sudden Sensorineural Hearing Loss
What this study did
NCT07255248 · Boston Children's Hospital
2026-03-01 – 2028-01-02 · Hoffa's Fat Pad Impingement
What this study did
NCT06489626 · F. Johannes Plate
2025-11-01 – 2027-12-01 · Arthritis Knee, Knee Osteoarthritis, Pain, Postoperative
What this study did
NCT02283996 · Massachusetts General Hospital
2014-11 – 2027-12 · Adhesive Capsulitis, Frozen Shoulder, Shoulder Frozen
What this study did
NCT05097976 · Rush University Medical Center
2022-03-01 – 2027-12 · Total Knee Arthroplasty
What this study did
NCT07788456 · Institute of Hematology & Blood Diseases Hospital, China
2026-06-22 – 2027-06-30 · ITP - Immune Thrombocytopenia
What this study did
NCT05929755 · Hardeep Singh
2023-05-12 – 2027-05 · Muscle Weakness, Pain, Postoperative, Paresthesia, Pain, Muscle
What this study did
NCT07077486 · Tongji Hospital
2025-08-25 – 2027-03-25 · Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus
What this study did
NCT06924983 · Yong Jiang
2025-05-01 – 2027-01-31 · Stroke, Intracerebral Hemorrhage Basal Ganglia, Methylprednisolone, Surgery
What this study did
NCT06921616 · Yong Jiang
2025-05-01 – 2027-01-31 · Stroke, Intracerebral Hemorrhage Lobar, Methylprednisolone, Surgery
What this study did
NCT06483204 · Vanderbilt University Medical Center
2026-01 – 2027-01 · Edema, Bruising, Nasal Obstruction, Postoperative Pain, Postoperative Nausea, Postoperative Complications
What this study did
NCT07393503 · State University of New York at Buffalo
2025-09-17 – 2027-01 · Musculoskeletal Pain
What this study did
NCT06510114 · Third Affiliated Hospital, Sun Yat-Sen University
2024-07 – 2026-12 · Graves Ophthalmopathy
What this study did
NCT04177433 · University of Alberta
2020-12-02 – 2025-12-31 · Osteoarthritis of the Carpometacarpal Joint, Thumb Osteoarthritis
What this study did
NCT05220319 · Ziekenhuis Oost-Limburg
2022-02-16 – 2025-10-28 · Inflammatory Response, Weakness, Muscle
What this study did
NCT06762145 · Xiao-dong Zhuang
2025-01-01 – 2025-07-31 · Transcatheter Aortic Valve Replacemen, Left Bundle Branch Block
What this study did
NCT05859269 · Emory University
2023-10-16 – 2025-07-23 · Knee Arthritis
What this study did
NCT05927233 · Aga Khan University
2023-04-01 – 2025-06-30 · Cyanotic Heart Disease, Cardiopulmonary Bypass
What this study did
NCT06041451 · First Affiliated Hospital of Wenzhou Medical University
2013-01-02 – 2025-01-31 · Guillain-Barre Syndrome
What this study did
NCT06623370 · Konya City Hospital
2024-10-01 – 2025-01-20 · Sugammadex Reversal Time, Muscle Weakness
What this study did
NCT06932367 · Ali Gur
2021-08-01 – 2025-01-02 · Low Back Pain
What this study did
NCT03898154 · C. Liam Dwyer
2019-07-10 – 2024-12-19 · Distal Radius Fracture
What this study did
NCT06076824 · Hospital General Universitario de Alicante
2023-08-12 – 2024-09-01 · Heart Block, Aortic Stenosis, Bundle-Branch Block
What this study did
NCT02769689 · University Hospital, Clermont-Ferrand
2019-06-12 – 2024-07-20 · Multiple Sclerosis
What this study did
NCT05604859 · Qin Ning
2022-08-19 – 2024-06-30 · Severe Fever With Thrombocytopenia Syndrome
What this study did
NCT05666336 · Fen Li
2022-12-31 – 2024-06-30 · Systemic Lupus Erythematosus
What this study did
NCT04773392 · University of Southern California
2021-11-23 – 2024-02-23 · Kidney Transplantation, Kidney Transplant Rejection
What this study did
NCT03636165 · Beijing Tiantan Hospital
2022-09-01 – 2023-12 · Pain, Postoperative, Post-Craniotomy Headache
What this study did
NCT05329740 · Shanghai Zhongshan Hospital
2022-02-07 – 2023-11-29 · Methylprednisolone, Glucocorticoid, Aortic Dissection, Organ Dysfunction
What this study did
Early phase / not applicable (85)
Rheumatoid Arthritis
NCT00006055 · Fairview University Medical Center
started 2000-03 · Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
What this study did
Ulcerative Colitis
NCT07257588 · Xijing Hospital of Digestive Diseases
2024-09-30 – 2025-12-31 · Ulcerative Colitis
What this study did
NCT00152620 · University of Chicago
2004-06 – 2007-05 · Inflammatory Bowel Disease (IBD)
What this study did
Other / comorbidity
NCT05925309 · Children's Hospital of Fudan University
2023-07-01 – 2029-12-31 · Biliary Atresia, Cholangitis, Anti-Bacterial Agents
What this study did
NCT07175649 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2025-10 – 2029-12 · Ischemic Stroke, Acute
What this study did
NCT07554885 · Guangzhou Institute of Respiratory Disease
2026-04 – 2029-10 · Immune Checkpoint Inhibitor-Related Pneumonitis, Drug-Related Side Effects and Adverse Reactions, Neoplasms
What this study did
NCT07328906 · University of Belgrade
2026-01 – 2029-01 · Postimplantation Syndrome, Myocardial Injury, MACE, Mortality
What this study did
NCT07568496 · Mahidol University
2026-05-12 – 2028-11-01 · Migraine Disorders, Medication Overuse Headache, Greater Occipital Nerve Block
What this study did
NCT07804199 · VA Office of Research and Development
2026-09-29 – 2028-01-01 · Knee Osteoarthritis
What this study did
NCT06922669 · General Hospital of Shenyang Military Region
2025-06-24 – 2027-09-30 · Drug Induced Liver Injury
What this study did
NCT06693856 · Zou Junjie
2025-01-01 – 2026-12-31 · Graves Ophthalmopathy
What this study did
NCT03647852 · Children's Hospital of Fudan University
2019-09-01 – 2026-10-30 · Henoch-Schönlein Purpura
What this study did
NCT06631976 · Medical University of Lodz
2024-06-04 – 2026-09 · Supraspinatus Injury, Sleep Disturbance
What this study did
NCT03924791 · C.L.A.Vleggeert-Lankamp
2019-06-01 – 2026-07 · Sciatica, Sciatica Due to Intervertebral Disc Disorder, Sciatic Radiculopathy
What this study did
NCT07187037 · Konya City Hospital
2025-10-01 – 2026-04-30 · Neuromuscular Block, Residual, Pain, Postoperative Nausea
What this study did
NCT03390387 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology
2015-11 – 2025-11 · Childhood Acute Lymphoblastic Leukemia
What this study did
NCT05914350 · Tanta University
2023-06-23 – 2025-03-23 · the Efficacy of Ultrasound Guided Sacroiliac Injection of Ozone, Platelet Rich Plasma (PRP) or Steroid for Treatment of Sacroiliitis
What this study did
NCT07918092 · Abant Izzet Baysal University
2023-10-16 – 2025-01-02 · Impacted Mandibular Third Molars
What this study did
NCT05349071 · Guangdong Provincial People's Hospital
2022-05-01 – 2024-10-01 · Methylprednisolone, Thoracic Endovascular Repair, Post-implantation Syndrome, Type B Aortic Dissection
What this study did
NCT03542279 · Xuanwu Hospital, Beijing
2020-11-25 – 2024-09-12 · Autoimmune Encephalitis
What this study did
NCT05930236 · Erasme University Hospital
2023-04-21 – 2024-06 · Chronic Low-back Pain, Lumbar Facet Joint Syndrome
What this study did
NCT05717374 · Mansoura University
2023-02-13 – 2023-12-01 · Caudal Block
What this study did
NCT05893771 · Menoufia University
2023-06-07 – 2023-11-27 · Postoperative Pain
What this study did
NCT05137522 · Beijing Friendship Hospital
2021-07-01 – 2023-07-01 · Chidamide, Hemophagocytic Lymphohistiocytosis
What this study did
NCT04129697 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-01-01 – 2022-12-31 · Dexamethasone or Methylprednisolone; Sudden Hearing Loss; Intratympanic Steroid
What this study did
NCT03160651 · Erasme University Hospital
2018-02-09 – 2022-12 · Alcoholic Hepatitis
What this study did
NCT04681937 · Bezmialem Vakif University
2021-06-01 – 2022-09-15 · Partial Tear of Rotator Cuff, Rotator Cuff Tears
What this study did
NCT04938037 · TC Erciyes University
2021-06-01 – 2022-08-05 · Chronic Shoulder Pain
What this study did
NCT02367560 · Lakehead University
2015-07 – 2022-06 · Calcific Tendinitis
What this study did
NCT04810819 · Qianfoshan Hospital
2021-07-01 – 2021-12-30 · Methylprednisolone;Dihydroxypropyltheophylline;One Lung Ventilation;Respiratory Dynamics
What this study did
NCT05649878 · Edda Sciutto Conde
2021-11-05 – 2021-11-12 · Methylprednisone Administration, Intranasal Administration, Intravenous Administration, Healthy Subjects
What this study did
NCT02539394 · Hospital for Special Surgery, New York
2015-08 – 2021-11-12 · Cervical Disc Herniation, Cervical Degenerative Disc Disease, Cervical Spondylotic Myelopathy, Dysphagia, Osteoarthritis of Cervical Spine
What this study did
NCT04593706 · Tel-Aviv Sourasky Medical Center
2020-11-01 – 2021-10-31 · Keloid, Hypertrophic Scar, Scars, Scarring
What this study did
NCT05291793 · Nevsehir Haci Bektas Veli University
2020-04-01 – 2021-08-01 · Gonarthrosis; Primary
What this study did
NCT01560052 · The George Institute
2012-05-05 – 2021-07-23 · IgA Glomerulonephritis
What this study did
NCT03492255 · University of Sao Paulo General Hospital
2018-04-12 – 2021-07-02 · Systemic Lupus Erythematosus (SLE)
What this study did
NCT04816253 · Al-Azhar University
2021-02-10 – 2021-06-20 · Preventing Postextraction Complication
What this study did
NCT04559113 · Lahore General Hospital
2020-05-01 – 2020-12-30 · SARS-CoV Infection, SARS (Severe Acute Respiratory Syndrome)
What this study did
NCT02711982 · Shanghai Changzheng Hospital
2010-01 – 2020-12 · Traumatic Optic Neuropathy
What this study did
NCT03974867 · Eye & ENT Hospital of Fudan University
2019-07 – 2020-12 · Vestibular Vertigo, Sudden Hearing Loss
What this study did
NCT02664493 · Samsung Medical Center
2016-02 – 2020-07 · Chronic Renal Failure
What this study did
NCT04273321 · Beijing Chao Yang Hospital
2020-02-14 – 2020-04-15 · COVID-19, Novel Coronavirus Pneumonia
What this study did
NCT02303587 · Beijing Children's Hospital
2014-12 – 2019-10-16 · Mycoplasma Pneumoniae Pneumonia
What this study did
NCT03742466 · Assiut University
2018-11-10 – 2019-09-30 · Carpal Tunnel Syndrome, Chronic Pain, Scleroderma
What this study did
NCT01579513 · Medical University of South Carolina
2012-06 – 2018-12-19 · Congenital Heart Disease, Disorder of Fetus or Newborn
What this study did
NCT02594241 · Kristian Kiim Jensen
2016-03 – 2018-11 · Hernia, Ventral
What this study did
NCT01156883 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2010-04 – 2017-10-31 · Leukemia
What this study did
NCT06900907 · Batman University
2017-03-01 – 2017-09-22 · Tooth Impaction | {Tooth} | Dental, Corticosteroid, Hyaluronic Acid, Ozone, Laser Therapy
What this study did
NCT01755338 · Sahlgrenska University Hospital
2012-12 – 2017-02 · Aortic Stenosis
What this study did
NCT02167698 · Post Graduate Institute of Medical Education and Research, Chandigarh
2014-02 – 2016-12 · Acute Respiratory Distress Syndrome (ARDS)
What this study did
Used as active comparator (71)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (14)
Rheumatoid Arthritis
NCT03511625 · Attune Health Research, Inc.
2018-10-02 – 2024-12-03 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT06970743 · BeOne Medicines
2025-05-29 – 2029-11-30 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT06532318 · Obafemi Awolowo University Teaching Hospital
2024-07-24 – 2025-06-23 · Trigger Finger Disorder
What this study did
NCT04791202 · Christine M. Kleinert Institute for Hand and Microsurgery
2021-04-01 – 2022-07-01 · Pain, Satisfaction, Patient, Functionality
What this study did
NCT05002517 · Biogipuzkoa Health Research Institute
2020-09-03 – 2021-10-31 · COVID-19 Pneumonia
What this study did
NCT04980105 · University of Wasit
2020-03-02 – 2021-10-01 · Osteoarthritis, Knee
What this study did
NCT04345445 · University of Malaya
2020-04-15 – 2020-10-31 · COVID-19
What this study did
NCT03018535 · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
2012-01 – 2019-12 · Glomerulonephritis, Membranous
What this study did
NCT01955187 · Hospital Universitario 12 de Octubre
2014-01 – 2019-06-26 · MEMBRANOUS NEPHROPATHY
What this study did
NCT02666703 · University Medical Centre Ljubljana
2016-02-01 – 2018-06 · Cardiopulmonary Bypass
What this study did
NCT00984984 · Rennes University Hospital
2008-03 – 2014-06 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT00241254 · University Hospital, Bordeaux
2005-12 – 2012-03 · Multiple Sclerosis, Chronic Progressive
What this study did
NCT00561067 · Niguarda Hospital
2008-04 – 2008-07 · Spinal Cord Injury
What this study did
Phase 2/3 (9)
Other / comorbidity
NCT07852195 · ECOG-ACRIN Cancer Research Group
2027-01-06 – 2030-03-31 · Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
What this study did
NCT07703280 · DuoGenic StemCells Corporation (DGSC)
2026-09-30 – 2029-12-31 · Knee Osteoarthritis
What this study did
NCT05748561 · Asociación para Evitar la Ceguera en México
2022-04-05 – 2024-04-05 · Toxic Optic Neuropathy, Treatment, Methylprednisolone, Erythropoietin
What this study did
NCT04480775 · ghada fouad
2020-07-15 – 2020-12-15 · Major Abdominal Surgery
What this study did
NCT01957631 · King Hamad University Hospital, Bahrain
2013-06 – 2019-09 · Plantar Fasciitis
What this study did
NCT03289338 · Post Graduate Institute of Medical Education and Research, Chandigarh
2016-06-01 – 2018-12-31 · Charcot Arthropathy, Diabetes Complications
What this study did
NCT01809132 · Mack Mitchell
2013-09 – 2018-10 · Acute Alcoholic Hepatitis
What this study did
NCT01907204 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2013-07 – 2014-01 · Sinusitis
What this study did
NCT00733096 · Johns Hopkins University
2008-08 – 2011-03 · Lumbosacral Radiculopathy
What this study did
Phase 2 (11)
Other / comorbidity
NCT07594912 · Sun Yat-sen University
2026-08 – 2028-04 · Thyroid Eye Disease, TED, Graves Ophthalmopathy, Optic Neuropathy
What this study did
NCT06223074 · Universidad Nacional Autonoma de Mexico
2023-01-09 – 2026-07-05 · Multiple Sclerosis Relapsing Remitting, Treatment
What this study did
NCT04876534 · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
2019-12-18 – 2026-03-18 · Graves Ophthalmopathy
What this study did
NCT05005637 · Fakultas Kedokteran Universitas Indonesia
2021-08-27 – 2024-11-20 · Tuberculous Uveitis
What this study did
NCT03674099 · Tomas Olsson
2018-10-01 – 2023-07-30 · Multiple Sclerosis
What this study did
NCT03067753 · Zhejiang Cancer Hospital
2016-12 – 2019-09 · Cerebral Radiation Necrosis
What this study did
NCT04532736 · Dokuz Eylul University
2017-09-02 – 2019-05-05 · Nasal Polyposis
What this study did
NCT00230035 · National Institute of Allergy and Infectious Diseases (NIAID)
started 2005-09 · Systemic Lupus Erythematosus
What this study did
NCT01114503 · GlaxoSmithKline
2010-07-07 – 2012-08-29 · Graves Ophthalmopathy
What this study did
NCT01039103 · Lakefront Biotherapeutics NV
2009-12 – 2011-11 · Acute Exacerbation of Remitting Relapsing Multiple Sclerosis, Clinically Isolated Syndrome
What this study did
NCT01216631 · University of Leeds
2010-09 – 2011-08 · Spondylarthropathies
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT04988425 · Shanghai Changzheng Hospital
2022-09-01 – 2023-08-30 · Spinal Cord Injuries
What this study did
NCT01783847 · Tehran University of Medical Sciences
2015-02 – 2017-02 · Traumatic Optic Neuropathy
What this study did
Phase 1 (4)
Other / comorbidity
NCT06707389 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-12-25 – 2027-06-01 · Sudden Deafness, Sensorineural Hearing Loss
What this study did
NCT04051203 · University of Calgary
2019-02-01 – 2023-12-01 · Occipital Neuralgia, Headache
What this study did
NCT01977781 · Massachusetts Eye and Ear Infirmary
2013-12 – 2014-09 · Ocular GVHD
What this study did
NCT01049451 · University of Southern California
2009-11 – 2013-07 · Multiple Sclerosis
What this study did
Phase 4 (15)
Asthma
NCT07731217 · Istanbul Medeniyet University
2025-09-01 – 2026-07-15 · Status Asthmaticus, Asthma (Diagnosis), Asthma Exacerbations
What this study did
NCT00627731 · Hamamatsu University
2007-06 – 2009-10 · Asthma
What this study did
Crohn's Disease
NCT00554710 · Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
2001-05 – 2004-01 · Crohn's Disease
What this study did
Rheumatoid Arthritis
NCT01308255 · University of Leeds
2006-09 – 2011-02 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07265258 · Innovent Biologics (Suzhou) Co. Ltd.
2026-07-30 – 2028-12-30 · Thyroid Eye Disease
What this study did
NCT06268704 · University of New Mexico
2024-03-27 – 2027-05-01 · Sacroiliac Joint Dysfunction, Sacro-Iliac Spondylosis
What this study did
NCT06717529 · Edin Mešanović
2023-01-01 – 2024-09-30 · Osteoarthritis (OA) of the Knee, Osteoarthritis, Osteoarthritis in the Knee, Osteoarthritis of Knee, Osteoarthritis of the Knees, Osteoarthritis of Knee Joint, Osteoarthritis Knee, Osteoarthritis of the Knee
What this study did
NCT06000709 · University of Manitoba
2023-10-20 – 2024-07-31 · Osteoarthritis, Knee, Chronic Knee Pain
What this study did
NCT01838174 · University of Colorado, Denver
2013-05 – 2022-01-13 · Multiple Sclerosis
What this study did
NCT04900948 · National Medical Research Center for Children's Health, Russian Federation
2017-12-10 – 2020-04-25 · Atopic Dermatitis
What this study did
NCT03694821 · UConn Health
2018-07-05 – 2019-07-16 · Osteoarthritis
What this study did
NCT03948191 · Dalian University
2017-10-16 – 2019-03-31 · Thyroid-Associated Ophthalmopathy
What this study did
NCT02403856 · Nantes University Hospital
2015-04-04 – 2017-11-13 · Calcifying Tendinitis of Shoulder
What this study did
NCT01995019 · Uppsala University
2013-12-10 – 2017-03-15 · Arthralgia, TMJ
What this study did
NCT01144143 · Herbert Lindsley, MD
2007-07 – 2011-01 · Osteoarthritis of the Knee
What this study did
Early phase / not applicable (16)
Other / comorbidity
NCT07883876 · Ankara Etlik City Hospital
2026-10 – 2027-09 · Lateral Epicondylitis
What this study did
NCT05842681 · Assiut University
2023-06-01 – 2027-02-28 · Idiopathic Pulmonary Fibrosis
What this study did
NCT06763848 · Third Affiliated Hospital, Sun Yat-Sen University
2025-04-25 – 2026-12-31 · Neuromyelitis Optica Spectrum Disorders
What this study did
NCT07628166 · Irfan Üstündağ
2026-03-02 – 2026-04-09 · Impacted Mandibular Third Molar Extraction, Postoperative Pain Control, Postoperative Edema and Pain
What this study did
NCT05765266 · Arthrex, Inc.
2024-05-13 – 2026-02-09 · Knee Osteoarthritis
What this study did
NCT05925166 · Lihua Duan
2020-09-01 – 2026-01-31 · Acute Gout
What this study did
NCT06710704 · Tanta University
2024-04-01 – 2024-10-24 · Transcutaneous, Pulsed Radiofrequency, Corticosteroids Injections, Pain, Lateral Epicondylitis
What this study did
NCT06131593 · Kasr El Aini Hospital
2023-12-01 – 2024-04-20 · Local Anesthetic, Ultrasound, Pain, Acute
What this study did
NCT05971004 · Tiss'You srl
2022-04-13 – 2023-04-04 · Collateral Ligament Injury of Stifle Joint
What this study did
NCT05339542 · Minia University
2022-03-10 – 2022-07-02 · Plantar Fascitis
What this study did
NCT04808856 · Shanghai 10th People's Hospital
2021-04-01 – 2022-04-01 · Gout
What this study did
NCT05707572 · Dundee Podiatry Clinic
2014-09 – 2019-09-30 · Morton Neuroma
What this study did
NCT02304094 · Queen Margaret University
2015-10 – 2017-04 · Neuroma, Human Forefoot
What this study did
NCT02669303 · American University of Beirut Medical Center
2015-09 – 2017-01-01 · Shoulder Impingement Syndrome
What this study did
NCT02334475 · Post Graduate Institute of Medical Education and Research, Chandigarh
2013-07 – 2014-12 · Chronic Pain
What this study did
NCT01554930 · Jiangxi Qingfeng Pharmaceutical Co. Ltd.
2010-05 – 2011-12 · Hand, Foot, and Mouth Disease
What this study did
Appears in other studies (43)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (11)
Rheumatoid Arthritis
NCT00299104 · Genentech, Inc.
2006-01 – 2013-07 · Rheumatoid Arthritis
What this study did
NCT00578305 · Hoffmann-La Roche
2007-11 – 2013-05 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07623668 · Oculis
2026-05-28 – 2028-12 · Optic Neuritis
What this study did
NCT04963296 · Hoffmann-La Roche
2021-10-26 – 2028-03-13 · Systemic Lupus Erythematosus
What this study did
NCT03139604 · Incyte Corporation
2017-07-19 – 2020-07-13 · Graft-versus-host Disease (GVHD)
What this study did
NCT00657059 · Sun Yat-sen University
2007-09 – 2019-05 · IgA Nephropathy
What this study did
NCT02398994 · Guy's and St Thomas' NHS Foundation Trust
2015-03 – 2016-03 · Myelitis, Transverse, Neuromyelitis Optica
What this study did
NCT00282503 · Mallinckrodt
2006-01 – 2007-06 · Acute Graft-versus-Host Disease
What this study did
NCT00053976 · Dana-Farber Cancer Institute
2001-01 – 2004-11 · Graft Versus Host Disease
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT02647255 · Peking University First Hospital
2016-03 – 2020-10 · Glomerulonephritis, IGA, Kidney Diseases, Acute Renal Insufficiency, Rapidly Progressive Glomerulonephritis
What this study did
NCT02956122 · Baxalta now part of Shire
2017-04-26 – 2018-05-03 · Graft Versus Host Disease
What this study did
Phase 2 (13)
Other / comorbidity
NCT04918147 · National Institute of Allergy and Infectious Diseases (NIAID)
2021-10-13 – 2024-01-04 · IgG4 Related Disease, IgG4-RD
What this study did
NCT02550652 · Hoffmann-La Roche
2015-11-13 – 2023-08-02 · Lupus Nephritis
What this study did
NCT02495077 · National Institute of Allergy and Infectious Diseases (NIAID)
2015-11-02 – 2021-07-23 · Kidney Transplant
What this study did
NCT03110848 · University of Pisa
2020-06-01 – 2021-04-30 · Thyroid Associated Ophthalmopathy, Hypercholesterolemia
What this study did
NCT03054259 · University of Leeds
2017-09-21 – 2020-02 · Systemic Lupus Erythematosus Arthritis
What this study did
NCT01086540 · National Institute of Allergy and Infectious Diseases (NIAID)
2011-06-24 – 2019-12-15 · Systemic Sclerosis-Associated PAH
What this study did
NCT02545959 · Centre Hospitalier de PAU
2015-11-30 – 2019-09-02 · Multiple Sclerosis, Chronic Progressive, Nervous System Diseases
What this study did
NCT01332617 · University of Louisville
2011-04 – 2019-02 · Myeloma
What this study did
NCT02569437 · Icahn School of Medicine at Mount Sinai
2014-09 – 2016-08 · Polyp of Nasal Sinus
What this study did
NCT01085097 · Teva Branded Pharmaceutical Products R&D, Inc.
2010-09-01 – 2012-10-24 · Lupus Nephritis
What this study did
NCT00332696 · Novartis Pharmaceuticals
2005-09 – 2008-09 · Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis
What this study did
NCT00367497 · Keio University
2005-08 – 2007-11 · Lymphoma, Non-Hodgkin
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT00752479 · Mario Negri Institute for Pharmacological Research
2008-05 – 2013-12 · Kidney Transplant
What this study did
Phase 1 (1)
Other / comorbidity
NCT02614612 · Incyte Corporation
2015-12 – 2018-08 · Graft-versus-host Disease (GVHD)
What this study did
Phase 4 (10)
Asthma
NCT00393367 · Children's Hospital of Philadelphia
2006-12 – 2007-11 · Asthma, Acute Asthma, Reactive Airway Exacerbation
What this study did
Ulcerative Colitis
NCT07258771 · Berinstein, Jeffrey
2026-01-16 – 2030-12 · Ulcerative Colitis Acute
What this study did
Other / comorbidity
NCT04192656 · Beijing Tsinghua Chang Gung Hospital
2019-11-01 – 2029-12 · Sudden Hearing Loss, Obstructive Sleep Apnea
What this study did
NCT03098225 · University of Pisa
2024-01-01 – 2027-03-31 · Thyroid Associated Ophthalmopathy
What this study did
NCT04826237 · Northwestern University
2023-02-09 – 2025-10-30 · Sudden Sensorineural Hearing Loss
What this study did
NCT05941130 · Implantology Institute
2022-07-01 – 2024-04-30 · Molar, Third, Third Molar Surgery, Soft Tissue Swelling, Pain, Postoperative, Quality of Life
What this study did
NCT02339142 · University of British Columbia
2015-01 – 2019-12 · Graves Ophthalmopathy
What this study did
NCT02292082 · Hospital for Special Surgery, New York
2014-11 – 2016-08 · Osteoarthritis
What this study did
NCT01817322 · Samsung Medical Center
2011-06 – 2013-08 · Chronic Renal Disease
What this study did
Early phase / not applicable (5)
Other / comorbidity
NCT02464696 · M.D. Anderson Cancer Center
2015-10-06 – 2026-10-01 · Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
What this study did
NCT05480566 · Hasselt University
2022-06-01 – 2023-12-01 · Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Exacerbation of COPD
What this study did
NCT02591953 · Rush University Medical Center
2015-11 – 2019-05 · Biceps Tendonitis, Injection
What this study did
NCT02036125 · Université de Sherbrooke
2013-10 – 2015-12 · Carpal Tunnel Syndrome
What this study did
NCT00348413 · Singapore National Eye Centre
2003-06 – 2008-07 · Graves Ophthalmopathy
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Asthma: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Methylprednisolone: this drugApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Albuterol (Armstrong Albuterol HFA)ApprovedSmall moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Albuterol (Ventolin)ApprovedSmall moleculeBeta-2 adrenergic receptorWeak signalNo reviewed efficacy summary in this indication
Albuterol / Budesonide (Airsupra)ApprovedCombinationBeta-2 adrenergic receptor, Glucocorticoid receptorReliable signal
NCT05505734: Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212
NCT03769090: Number of Participants With a Severe Asthma Exacerbation Event (From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.): BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) 207/1013 | BDA MDI 80/180 μg (Full Analysis Set) 241/1054 vs AS MDI 180 μg (Full Analysis Set; >=12 Years) 266/1014 | AS MDI 180 μg (Full Analysis Set) 276/1056
Albuterol Sulfate (Amphastar)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Albuterol Sulfate (Proventil HFA)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
AminophyllineApprovedSmall moleculePhosphodiesterase (multi-subtype)not yet gradedNo reviewed efficacy summary in this indication
Beclomethasone (QVAR)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT02040766: Baseline-adjusted trough morning percent predicted FEV1, AUEC(0-12 wk) vs placebo: BDP 80 ug/day BAI +2.81 (95% CI 0.80 to 4.82), p=0.0063; BDP 160 ug/day BAI +0.63, p=0.5332; BDP 80 ug/day MDI +0.92, p=0.3649; BDP 160 ug/day MDI +1.09, p=0.2823 (CT.gov posted results).
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
Benralizumab (Fasenra)ApprovedMonoclonal antibodyIL-5 receptor alpha, IL-5 receptor alpha (IL-5Rα / CD125); Fc region additionally engages FcγRIIIa on NK cells (ADCC), IL-5 receptor alpha (IL5RA) on eosinophils/basophilsReliable signal
NCT03170271: Annualized Rate of Asthma Exacerbations Over the Treatment Period (up to Week 24) (Baseline (Week 0) up to Week 24): Benralizumab 0.94 Events/year (95% CI 0.79 to 1.12) | Placebo 1.86 Events/year (95% CI 1.54 to 2.24)
NCT01928771: Annual asthma exacerbation rate: 0.73 events/year with benralizumab 30 mg q4w vs 1.33 with placebo (rate ratio 0.55, 95% CI 0.42-0.71; p<0.001); 0.65 events/year with benralizumab 30 mg q8w vs 1.33 with placebo (rate ratio 0.49, 95% CI 0.37-0.64; p<0.001).
Budesonide (Pulmicort)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide (Pulmicort Flexhaler)ApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00646321: Evening PEF (primary) better with once- or twice-daily budesonide/formoterol than budesonide alone (P<or=.027).
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicPartial signal
NCT04609878: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.281 Liters (Standard Error 0.018) | BGF MDI 320/28.8/9.6 μg BID 0.316 Liters (Standard Error 0.014) vs BFF MDI 320/9.6 μg BID 0.249 Liters (Standard Error 0.014) | Symbicort® pMDI 320/9 μg BID 0.22 Liters (Standard Error 0.014)
NCT04609904: Change From Baseline in FEV1 AUC0-3 (L) at Week 24 (Week 24): BGF MDI 320/14.4/9.6 μg BID 0.374 Liters (Standard Error 0.019) | BGF MDI 320/28.8/9.6 μg BID 0.354 Liters (Standard Error 0.015) vs BFF MDI 320/9.6 μg BID 0.219 Liters (Standard Error 0.015) | Symbicort® 320/9 μg BID 0.239 Liters (Standard Error 0.015)
Ciclesonide (Alvesco)ApprovedSmall moleculeGlucocorticoid receptorReliable signal
NCT00174720: FEV1 change from baseline, source's own labeled primary endpoint (average of weeks 12 and 16): ciclesonide 80mcg b.i.d. +0.30L (p<0.0001), 160mcg q.d. +0.19L (p<0.0001), 80 b.i.d./160 q.d. stepped +0.19L (p<0.0001), vs placebo +0.06L (p=0.0251); at week 16 alone, all ciclesonide arms significant vs placebo (p<=0.015), magnitude not given for week 16 alone
NCT00163397: Change in FEV1: non-inferiority of ciclesonide to budesonide demonstrated (one-sided p = 0.0021), confirmed in the ITT analysis
DepemokimabApprovedMonoclonal antibodyIL-5Partial signal
NCT04719832: Annualized Rate of Clinically Significant Exacerbations up to 52 Weeks (Up to Week 52): Placebo 1.11 Exacerbation per participant per year (95% CI 0.86 to 1.43) | GSK3511294 0.46 Exacerbation per participant per year (95% CI 0.36 to 0.58)
Desoximetasone (Topicort Spray)
Approved(overall)
Small moleculeGlucocorticoid receptor agonist
Partial signal(overall)
No reviewed efficacy summary in this indication
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT03782532: Change in pre-bronchodilator FEV1, baseline to Week 12: LS mean difference 0.31 L favoring dupilumab vs placebo (95% CI 0.23-0.39); p<0.0001 (primary analysis population, n=414).
Fluticasone Furoate (Arnuity Ellipta)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT00603278: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 100 µg OD 0.142 Liters (Standard Error 0.0403) | GW685698X 200 µg OD 0.173 Liters (Standard Error 0.0404) | GW685698X 300 µg OD 0.228 Liters (Standard Error 0.0402) | GW685698X 400 µg OD 0.215 Liters (Standard Error 0.0414) vs Placebo -0.065 Liters (Standard Error 0.0395) | FP 250 µg BID 0.16 Liters (Standard Error 0.0409)
NCT00603382: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 (Baseline and Week 8): GW685698X 25 µg OD 0.239 Liters (Standard Error 0.0428) | GW685698X 50 µg OD 0.266 Liters (Standard Error 0.042) | GW685698X 100 µg OD 0.341 Liters (Standard Error 0.0396) | GW685698X 200 µg OD 0.367 Liters (Standard Error 0.0428) vs Placebo 0.137 Liters (Standard Error 0.0428) | FP 100 µg BID 0.243 Liters (Standard Error 0.0411)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02924688: Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001).
NCT04937387: Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12 (100ug FF) (Baseline (pre-dose at Day 1) and Week 12): Fluticasone Furoate [FF] 100 ug/ Umeclidinium [UMEC] 62.5 ug/ Vilanterol [VI] 25 ug 0.136 Liters (Standard Error 0.0316) vs Fluticasone Furoate [FF] 100 Microgram[ug] / Vilanterol [VI] 25 ug 0.078 Liters (Standard Error 0.0321)
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorReliable signal
NCT01086384: Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010
NCT03248128: Absolute Weighted Mean of Forced Expiratory Volume in 1 Second (FEV1) (0-4 Hours) at Week 12 in 5-17 Year Old Population (Week 12): Participants Who Received FF/ VI FDC 2.082 Liters (Standard Deviation 0.7598) vs Participants Who Received FF 1.994 Liters (Standard Deviation 0.6998)
Fluticasone PropionateApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT00920959: Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) missed
Fluticasone Propionate / Salmeterol (Advair HFA)ApprovedCombinationGlucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptorPartial signal
NCT00448435: Adjusted Mean Change From Baseline in Morning PEF (Peak Expiratory Flow) During the 4-week Treatment Periods (Crossover Period Weeks 1-4, and 7-10): SFC 50/100 Mcg/Day 14.3 Liters/minute (Standard Error 4.53) vs SLM 50 Mcg + FP 100 Mcg/Day 17.1 Liters/minute (Standard Error 4.53)
Levalbuterol (Xopenex HFA)Approved—beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingWeak signal
NCT01691508: Number of Participants With the Indicated Percent Reduction From Baseline in Oral Corticosteroid (OCS) Dose During Weeks 20 to 24 While Maintaining Asthma Control (Baseline; Weeks 20 to 24): Mepolizumab 100 mg SC — 90 to 100%: 16/69; 75 to <90%: 12/69; 50 to <75%: 9/69; >0 to <50%: 7/69; No decrease /lack of asthma control/early WD: 25/69 vs Placebo — 90 to 100%: 7/66; 75 to <90%: 5/66; 50 to <75%: 10/66; >0 to <50%: 7/66; No decrease /lack of asthma control/early WD: 37/66
NCT01000506: Number of Clinically Significant Exacerbations of Asthma Per Year (From randomization (Week 0) to Week 52 or early withdrawal (EW)): Mepolizumab 75 mg IV 1.24 Exacerbations per year | Mepolizumab 250 mg IV 1.46 Exacerbations per year | Mepolizumab 750 mg IV 1.15 Exacerbations per year vs Placebo IV 2.4 Exacerbations per year
Mometasone Furoate / Formoterol Fumarate (Dulera / Zenhale)ApprovedSmall moleculeGlucocorticoid receptor; Beta-2 adrenergic receptorPartial signal
NCT00383240: Primary endpoint (FEV1 AUC(0-12h) change from baseline to week 12, L*h), MF/F 200/10 mcg vs MF 200 mcg alone: 3.19 (SD 3.98) vs 1.31 (SD 3.98); p<.001.
NCT00383552: AUC(0-12h) change from baseline to Week 12 in FEV1: MF/F 100/10 mcg BID +4.00 L*h (SD 3.71) vs MF 100 mcg BID +2.53 L*h (SD 3.71); ANCOVA p=0.001.
Montelukast (Singulair)ApprovedSmall moleculeCysteinyl leukotriene receptor 1 (CysLT1)Weak signal
NCT00489346: Primary endpoint (percentage of asthma rescue-free days over 12 months): montelukast 5mg QD (n=495) was non-inferior to fluticasone 100mcg BID (n=499) — 495+499=994, exactly matching this record's enrollment. LS mean difference -2.8% (95% CI -4.7% to -0.9%), within the pre-specified -7% noninferiority margin.
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEWeak signalNo reviewed efficacy summary in this indication
Primatene MistApprovedSmall moleculeAdrenergic receptor (non-selective, alpha+beta), Alpha-1 and beta-1/beta-2 adrenergic receptors, Adrenergic receptors, nonselectivePartial signal
NCT01460511: Primary endpoint, AUC0-6h of percent change in FEV1 at week 4: numerical benefit of epinephrine HFA over placebo, not statistically significant (two-sided p=0.125, per-protocol analysis; supported by the ITT and three sensitivity analyses). FDA judged the trial underpowered. missed
NCT01357642: Primary endpoint, AUC0-6h of percent change in FEV1 at week 12 (ITT): epinephrine HFA 250 mcg 40.59 (SD 56.09, n=248) vs placebo 12.76 (SD 55.77, n=61); mean difference 27.83 (95% CI 11.99 to 43.68), p<0.05. Epinephrine CFC active control: 35.67 (SD 45.70, n=64).
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
TerbutalineApprovedSmall moleculeBeta-2 adrenergic receptor (ADRB2)not yet gradedNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)ApprovedMonoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingReliable signal
NCT03347279: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma (From randomisation to Study Week 52.): Tezepelumab 210mg Q4W 0.93 events per year (95% CI 0.8 to 1.07) | Placebo 2.1 events per year (95% CI 1.84 to 2.39)
NCT03406078: Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control (Baseline to Week 48): Tezepelumab — >=90% to <=100% reduction: 40/74; >=75% to <90% reduction: 5/74; >=50% to <75% reduction: 10/74; >0% to <50% reduction: 5/74; no change or any increase: 14/74 vs Placebo — >=90% to <=100% reduction: 35/76; >=75% to <90% reduction: 4/76; >=50% to <75% reduction: 14/76; >0% to <50% reduction: 9/76; no change or any increase: 14/76 missed
Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT00772538: Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026)
NCT00565266: Change Between Week 14 and Week 0 in the Morning (AM) Peak Expiratory Flow (PEF) (AM PEF was measured daily during each of the three 14-week treatment periods. The primary analysis constructed the change between week 14 and week 0.): Tio + 1xICS 24.4 Liters per minute (Standard Error 4.2) vs LABA + 1xICS 18 Liters per minute (Standard Error 3.2) vs 2xICS -1.4 Liters per minute (Standard Error 3.5)
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptorReliable signal
NCT05292586: 1_Change From Baseline in FEV1 AUC0-12h Normalised by Time at Week 12 (Baseline (pre-dose on Week 0) and Week 12.): CHF 1535 pMDI 0.279 liter (95% CI 0.248 to 0.309) vs CHF 718 pMDI 0.174 liter (95% CI 0.143 to 0.206)
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
FenoterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signalNo reviewed efficacy summary in this indication
Fenoterol / Ipratropium BromidePhase 3Small moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination), Muscarinic acetylcholine receptor M3 and beta-2 adrenergic receptorReliable signal
NCT02182479: Primary, average FEV1 change from test-day baseline over 6 hours after dosing on day 85, non-inferiority of Respimat SMI (10/25 mcg and 20/50 mcg) vs pMDI (20/50 mcg): neither Respimat dose was inferior to the pMDI (p<0.001), met. Supportive: mean peak FEV1 increase on day 85 was 0.498 to 0.521 L with active treatment vs 0.215 and 0.240 L with placebo.
Indacaterol Maleate / Mometasone FuroatePhase 3—Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT02554786: Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016)
NCT02892344: Trough FEV1 (week 12): QMF149 150/80 μg 2.562 Liters (Standard Error 0.0134) | MF 200 µg 2.379 Liters (Standard Error 0.0134)
IpratropiumPhase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
MasitinibPhase 3Small moleculeKIT (c-Kit), also PDGFR and Lyn/Fyn kinasesPartial signal
NCT01449162: Annualized severe asthma exacerbation rate (SAER), primary population, overall treatment exposure: masitinib reduced SAER by 35% vs placebo; rate ratio 0.65 (95% CI 0.47-0.90; P=0.010)
NCT03771040: Severe asthma exacerbations: 29% reduction vs placebo (p=0.022) in patients with eosinophils above 150/uL
OcankitugPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
Oxitropium Bromide (Ba253BINEB)Phase 3Small moleculeMuscarinic acetylcholine receptor (M3)Weak signalNo reviewed efficacy summary in this indication
RademikibartPhase 3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Salbutamol HFA-152aPhase 3Small moleculeBeta-2 adrenergic receptorWeak signal
NCT06261957: Primary outcomes, safety (no formal efficacy test): participants with an adverse event in the treatment period 108/338 (HFA-152a) vs 36/112 (HFA-134a); none in the run-in period (0/471); serious adverse events 6/338 vs 3/112 (CT.gov posted results).
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
VilanterolPhase 3Small moleculeBeta-2 adrenergic receptorPartial signal
NCT00600171: Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036)
Glycopyrronium (PT001)Phase 2/3Small moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03358147: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412)
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2/3Monoclonal antibodyTSLPWeak signalFeatured results are safety only in this race
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
ARO-RAGEPhase 2RNA / oligonucleotideRAGE (receptor for advanced glycation end-products)Weak signalFeatured results are safety only in this race
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
ENV-294Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Freneslerbart / MevonlerbartPhase 2Monoclonal antibodyFel d 1 (major cat allergen protein)Reliable signal
NCT03838731: Primary endpoint, time to early asthmatic reaction at Week 1 following single dose: >4 hours (REGN1908-1909) vs 51 minutes (placebo), p=0.0083
FrevecitinibPhase 2Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
KT-621Phase 2Small moleculeSTAT6not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 2Antibody-derived scaffoldTSLP + IL-13Weak signalFeatured results are safety only in this race
PBF-680Phase 2—Adenosine A1 receptorPartial signal
NCT03774290: Trough FEV1 change from baseline at Day 16: placebo 2.88±0.10 L vs PBF-680 3.06±0.09 L; +180 mL mean increase over placebo (P=0.0816, pre-specified alpha=0.1)
QuisovalimabPhase 2Monoclonal antibodyLIGHT (TNFSF14)Partial signal
NCT05288504: Participants with an asthma-related event through week 14: AVTX-002 12 vs placebo 14 (CT.gov posted counts); the sponsor states the primary endpoint was not met. missed
RC1416Phase 2Multispecific antibodyIL-4 / IL-5 / IL-13not yet gradedNo reviewed efficacy summary in this indication
RilzabrutinibPhase 2Small moleculeBTKPartial signal
NCT05104892: Primary endpoint (LOAC events at Week 12): high-dose rilzabrutinib 36% relative risk reduction vs placebo (OR 0.584, 95% CI 0.253-1.349); low-dose 25% relative risk reduction (OR 0.570, 95% CI 0.202-1.608). missed
SunakimentPhase 2Antibody fragmentTSLPPartial signalFeatured results are safety only in this race

Large race: only the 63 furthest-along competitors are listed; 25 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(94 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Methylprednisolone to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (8)
November 2026 (4)
Phase 2Mandible Fracture, Edema Face, Pain Management, Corticosteroid InjectionRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11-30 · NCT07208799 · CT.gov ↗
What to watch
Phase 2Dysphagia, Laryngeal EdemaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11-30 · NCT06670521 · CT.gov ↗
What to watch
Phase 4Stroke, Intracerebral Hemorrhage Basal Ganglia, Methylprednisolone, SurgeryNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11-30 · NCT06924983 · CT.gov ↗
What to watch
Phase 4Stroke, Intracerebral Hemorrhage Lobar, Methylprednisolone, SurgeryNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2026-11-30 · NCT06921616 · CT.gov ↗
What to watch
December 2026 (4)
Phase 4Adhesive Capsulitis, Frozen Shoulder, Shoulder FrozenRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12 · NCT02283996 · CT.gov ↗
What to watch
Phase 2Blastic Plasmacytoid Dendritic Cell NeoplasmRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT04216524 · CT.gov ↗
What to watch
Phase 3Opioid Use, Lumbar Spinal Stenosis, Pain, Postoperative, Pain, BackRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT05058287 · CT.gov ↗
What to watch
Phase 4Multiple MyelomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2026-12-31 · NCT07101445 · CT.gov ↗
What to watch
2027 (33)
January 2027 (4)
Phase 4Musculoskeletal PainEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2027-01 · NCT07393503 · CT.gov ↗
What to watch
Early phase / not applicablePostimplantation Syndrome, Myocardial Injury, MACE, MortalityNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01 · NCT07328906 · CT.gov ↗
What to watch
Phase 2Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-01 · NCT03579875 · CT.gov ↗
What to watch
Phase 2Headaches Associated With Subarachnoid Hemorrhage (SAH)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-01-01 · NCT07054801 · CT.gov ↗
What to watch
February 2027 (2)
Phase 1/2Gaucher Disease, Type 2Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02 · NCT04411654 · CT.gov ↗
What to watch
Phase 2Episodic MigraineRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-02 · NCT05734625 · CT.gov ↗
What to watch
March 2027 (2)
Phase 4Chronic Planter FascitisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03 · NCT07394894 · CT.gov ↗
What to watch
Early phase / not applicableDrug Induced Liver InjuryRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-03-31 · NCT06922669 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1Multiple Myeloma in Relapse, Multiple Myeloma, RefractoryRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-01 · NCT06225310 · CT.gov ↗
What to watch
Phase 2B Acute Lymphoblastic Leukemia, B Lymphoblastic LymphomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-01 · NCT05303792 · CT.gov ↗
What to watch
Phase 2Plasma Cell Myeloma RefractoryActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-04-01 · NCT06356571 · CT.gov ↗
What to watch
May 2027 (2)
Phase 4Total Knee ArthroplastyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-30 · NCT05097976 · CT.gov ↗
What to watch
Phase 4ITP - Immune ThrombocytopeniaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-05-30 · NCT07788456 · CT.gov ↗
What to watch
June 2027 (4)
Phase 2Foot Injuries and Disorders, Ankle Injuries and Disorders, Achilles Tendon InjuryRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06 · NCT06780202 · CT.gov ↗
What to watch
Phase 2Acute Graft-versus-host Disease, Allogeneic Bone Marrow Transplantation, Adverse EffectsRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-01 · NCT06936566 · CT.gov ↗
What to watch
Phase 3Erythema MultiformeNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-01 · NCT06266221 · CT.gov ↗
What to watch
Phase 3Adenovirus Infections, HumanNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-06-30 · NCT07152600 · CT.gov ↗
What to watch
July 2027 (2)
Phase 1Thyroid Eye Disease, Graves Ophthalmopathy, Graves OrbitopathyNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-30 · NCT07762105 · CT.gov ↗
What to watch
Phase 1/2Cranial Nerve Disorder, Head and Neck Carcinoma, Oropharyngeal CarcinomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-07-31 · NCT04151082 · CT.gov ↗
What to watch
September 2027 (3)
Phase 2Total Knee Replacement, Knee ArthroplastyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09 · NCT05279092 · CT.gov ↗
What to watch
Phase 2Total Knee Replacement, Knee ArthroplastyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09 · NCT05736549 · CT.gov ↗
What to watch
Phase 1/2Crohn's DiseaseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-09-30 · NCT04224558 · CT.gov ↗
What to watch
October 2027 (3)
Phase 2aGVHDRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-01 · NCT07185633 · CT.gov ↗
What to watch
Phase 1/2Amyotrophic Lateral SclerosisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-15 · NCT07287397 · CT.gov ↗
What to watch
Phase 1/2X-Linked Myotubular MyopathyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-10-31 · NCT07052929 · CT.gov ↗
What to watch
November 2027 (2)
Phase 4Ulcerative ColitisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11 · NCT05867329 · CT.gov ↗
What to watch
Phase 4Hoffa's Fat Pad ImpingementRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-11-01 · NCT07255248 · CT.gov ↗
What to watch
December 2027 (6)
Phase 2GVHD, Acute, Stem Cell Transplant ComplicationsRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-30 · NCT07509749 · CT.gov ↗
What to watch
Phase 2Ischemia Stroke, Thrombectomy, Large Vessel OcclusionRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07516522 · CT.gov ↗
What to watch
Phase 2Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR)Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07902609 · CT.gov ↗
What to watch
Phase 3Acute Ischemic StrokeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07141303 · CT.gov ↗
What to watch
Phase 3Achilles Tendinopathy (AT)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT07650396 · CT.gov ↗
What to watch
Early phase / not applicableBiliary Atresia, Cholangitis, Anti-Bacterial AgentsRecruitingStudy of the molecule, not a specific product
Est. primary completion 2027-12-31 · NCT05925309 · CT.gov ↗
What to watch
2028 (26)
January 2028 (2)
Phase 2Thyroid-Associated OphthalmopathyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01 · NCT04936854 · CT.gov ↗
What to watch
Early phase / not applicableKnee OsteoarthritisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-01-01 · NCT07804199 · CT.gov ↗
What to watch
March 2028 (4)
Phase 2IgA Nephropathy (IgAN)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03 · NCT06676579 · CT.gov ↗
What to watch
Phase 3Myocarditis AcuteRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03 · NCT05150704 · CT.gov ↗
What to watch
Phase 2Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-01 · NCT07763210 · CT.gov ↗
What to watch
Phase 1/2Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-03-31 · NCT07525466 · CT.gov ↗
What to watch
April 2028 (2)
Phase 3Hand OsteoarthritisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-04 · NCT07371572 · CT.gov ↗
What to watch
Phase 2Sepsis, Acute Respiratory Distress SyndromeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-04-01 · NCT07511582 · CT.gov ↗
What to watch
June 2028 (2)
Phase 2Paraneoplastic Sensory NeuronopathyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06 · NCT06373211 · CT.gov ↗
What to watch
Phase 2/3Brain Metastases From Solid TumorsNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-06-30 · NCT07542288 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1Sacro-iliac Joint PainRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-07 · NCT06081101 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2AsthmaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-14 · NCT07455396 · CT.gov ↗
What to watch
Phase 3Acute MyocarditisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-08-16 · NCT06522100 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1/2Acute Respiratory Failure, Community-Acquired PneumoniaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-01 · NCT07357935 · CT.gov ↗
What to watch
Phase 4Sudden Sensorineural Hearing LossRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-09-10 · NCT06968507 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Crohn's DiseaseRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-10 · NCT03219359 · CT.gov ↗
What to watch
November 2028 (4)
Early phase / not applicableMigraine Disorders, Medication Overuse Headache, Greater Occipital Nerve BlockRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11-01 · NCT07568496 · CT.gov ↗
What to watch
Phase 2ThymomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11-19 · NCT06730308 · CT.gov ↗
What to watch
Phase 3PsittacosisNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11-30 · NCT07352865 · CT.gov ↗
What to watch
Phase 3InfluenzaNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-11-30 · NCT07351500 · CT.gov ↗
What to watch
December 2028 (6)
Early phase / not applicableIschemic Stroke, AcuteNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT07175649 · CT.gov ↗
What to watch
Early phase / not applicableImmune Checkpoint Inhibitor-Related Pneumonitis, Drug-Related Side Effects and Adverse Reactions, NeoplasmsNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12 · NCT07554885 · CT.gov ↗
What to watch
Phase 4Unruptured Intracranial Aneurysms, Cerebrovascular Event, Hemorrhagic Stroke, Methylprednisolone, Flow DiverterNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-01 · NCT07353749 · CT.gov ↗
What to watch
Phase 2Multiple SclerosisRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT02784210 · CT.gov ↗
What to watch
Phase 2Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic LeukemiaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT06317662 · CT.gov ↗
What to watch
Phase 4ShoulderNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2028-12-31 · NCT07902843 · CT.gov ↗
What to watch
2029 (14)
January 2029 (4)
Phase 3Acute Ischemic StrokeNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-01 · NCT06870448 · CT.gov ↗
What to watch
Phase 4Orthopedic SurgeriesEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2029-01 · NCT03661645 · CT.gov ↗
What to watch
Phase 3Cardiac Arrest;In-hospital Cardiac Arrest; Methylprednisolone; Vasopressin; Adrenaline; Randomized Clinical TrialRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-01-31 · NCT05139849 · CT.gov ↗
What to watch
Phase 4Traumatic Brain InjuryRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-01-31 · NCT07180277 · CT.gov ↗
What to watch
February 2029 (1)
Phase 2Neuroendocrine Cell Hyperplasia of InfancyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-02-28 · NCT06471556 · CT.gov ↗
What to watch
March 2029 (1)
Phase 3HepatectomyRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-03-27 · NCT07507643 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1Acute Gastrointestinal Graft-versus-host DiseaseEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2029-05-01 · NCT07803978 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic SyndromeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-06-30 · NCT01624805 · CT.gov ↗
What to watch
July 2029 (2)
Phase 3Diffuse Large B-Cell LymphomaRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-07-02 · NCT06717347 · CT.gov ↗
What to watch
Phase 4Pediatric Stroke, Arteriopathy, Arterial Ischemic StrokeEnrolling by invitationStudy of the molecule, not a specific product
Est. primary completion 2029-07-31 · NCT06040255 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2/3Kidney Transplant RejectionRecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-08-15 · NCT07412470 · CT.gov ↗
What to watch
September 2029 (1)
Phase 4Adrenal InsufficiencyNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-09-01 · NCT07703098 · CT.gov ↗
What to watch
November 2029 (1)
Phase 1/2Frontotemporal DementiaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2029-11-30 · NCT04408625 · CT.gov ↗
What to watch
December 2029 (1)
Phase 4Back Pain Lower Back, Neck Pain, Radiculopathy Multiple Sites, Spinal Stenosis Cervicothoracic Region, Spinal Stenosis Lumbar …RecruitingStudy of the molecule, not a specific product
Est. primary completion 2029-12 · NCT07762170 · CT.gov ↗
What to watch
2030 (7)
January 2030 (1)
Phase 1/2Lysosomal Diseases, Gangliosidosis, GM1RecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-01-01 · NCT03952637 · CT.gov ↗
What to watch
June 2030 (2)
Phase 3Rejection; Transplant, Kidney, Rejection; Transplant, PancreasRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-06 · NCT06474273 · CT.gov ↗
What to watch
Phase 2Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity …Active not recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-06-30 · NCT04305145 · CT.gov ↗
What to watch
August 2030 (2)
Phase 4Chronic Obstructive Pulmonary Disease (COPD)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-08-01 · NCT06892210 · CT.gov ↗
What to watch
Phase 4Community Acquired Pneumonia (CAP)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-08-01 · NCT06892197 · CT.gov ↗
What to watch
September 2030 (1)
Phase 4ACL Surgery, Pain ManagementRecruitingStudy of the molecule, not a specific product
Est. primary completion 2030-09 · NCT07158476 · CT.gov ↗
What to watch
October 2030 (1)
Phase 3Plasma Cell MyelomaActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2030-10-14 · NCT04270409 · CT.gov ↗
What to watch
2031 (4)
April 2031 (1)
Phase 3STEMI - ST Elevation Myocardial InfarctionRecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-04-20 · NCT07478003 · CT.gov ↗
What to watch
August 2031 (2)
Phase 4ACL ReconstructionNot yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-08 · NCT07605923 · CT.gov ↗
What to watch
Phase 1/2Parkinson DiseaseActive not recruitingStudy of the molecule, not a specific product
Est. primary completion 2031-08-31 · NCT04127578 · CT.gov ↗
What to watch
December 2031 (1)
Phase 3Lupus Nephritis, Systemic Lupus Erythematosus (SLE)RecruitingStudy of the molecule, not a specific product
Est. primary completion 2031-12 · NCT04702256 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 1/2CTNNB1 Neurodevelopmental SyndromeRecruitingStudy of the molecule, not a specific product
Est. primary completion 2032-12-31 · NCT07270549 · CT.gov ↗
What to watch
2035 (1)
September 2035 (1)
Phase 2/3Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma …Not yet recruitingStudy of the molecule, not a specific product
Est. primary completion 2035-09-01 · NCT07072585 · CT.gov ↗
What to watch

See the full readout calendar ↗